Keyword: Celgene

Several big drugmakers have posted big share price gains in the first nine months of the year, while other companies have seen only modest declines.

Expanding Otezla's market to scalp psoriasis could be challenging for Celgene, in light of hurdles such as mounting competition.

Jackie Fouse has been a prime CEO candidate since leaving Celgene, and it’s Agios that finally gets to claim her as its next skipper.

Juno didn't immediately report CAR-T trial deaths, investors argued in a lawsuit, and now the sides have inked a $24 million settlement.

RBC Capital Markets investors picked an oncology expert as their top candidate to replace Gilead CEO John Milligan.

Celgene is extracting volume-driven sales growth as the entire industry has come under scrutiny for its pricing.

Celgene ended a losing streak Monday with a Revlimid trial win, and one analyst thinks more rosy pipeline events could follow soon.

Agios Pharmaceuticals has scored its first FDA nod for a wholly-owned medicine, Tibsovo.

A patent ruling for Novartis will give Celgene time to secure FDA approval for its Gilenya rival and persuade physicians that it's a safer MS pill.

Though Trump convinced Pfizer to delay its planned price increases, Celgene, Roche and Novo have gone through with their own increases in July.